Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment-Reference-Cited by-同舟云学术

Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment

Published:2019-02-02 Issue:7 Volume:69 Page:1229-1231
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Polsfuss Silke¹,Hofmann-Thiel Sabine²³,Merker Matthias⁴⁵,Krieger David⁶,Niemann Stefan⁴⁵,Rüssmann Holger¹,Schönfeld Nicolas⁶,Hoffmann Harald²³,Kranzer Katharina⁷⁸

Affiliation:

1. Institute for Microbiology, Immunology and Laboratory Medicine, Helios Klinikum Emil von Behring, Berlin

2. Synlab Gauting, synlab MVZ Humane Genetik

3. IML red GmbH, Tuberculosis Supranational Reference Laboratory, Gauting

4. Molecular and Experimental Mycobacteriology, Research Center Borstel

5. German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel

6. Department of Pneumology, Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin

7. National Reference Laboratory for Mycobacteria, Research Center Borstel, Borstel, Germany

8. Clinical Research Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom

Abstract

Abstract Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired during treatment of a patient with XDR tuberculosis.

Funder

German Center for Infection Research

the Deutsche Forschungsgemeinschaft

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/69/7/1229/30002833/ciz074.pdf

Reference13 articles.

1. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis;Dheda;Lancet Respir Med,2017

2. Delamanid for multidrug-resistant pulmonary tuberculosis;Gler;N Engl J Med,2012

3. Delamanid and bedaquiline resistance in Mycobacterium tuberculosis ancestral Beijing genotype causing extensively drug-resistant tuberculosis in a Tibetan refugee;Hoffmann;Am J Respir Crit Care Med,2016

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design and synthesis of Thieno[3, 2-b]pyridinone derivatives exhibiting potent activities against Mycobacterium tuberculosis in vivo by targeting Enoyl-ACP reductase;European Journal of Medicinal Chemistry;2024-12

2. The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis—lessons from the South African experience;The Lancet Infectious Diseases;2024-09

3. Identification of Mutation Combinations in Genome-Wide Association Studies: Application for Mycobacterium tuberculosis;Pattern Recognition and Image Analysis;2024-06

4. First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug;Journal of Antimicrobial Chemotherapy;2024-04-24

5. Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis;Genome Medicine;2024-02-19